Vol. 7, Issue 1, Part B (2025)

Bacopa monnieri, commonly referred to as Brahmi, has garnered considerable scientific attention for its potential role in enhancing brain health and cognitive performance. This review synthesizes data from various studies to explore its therapeutic potential in managing neurological conditions, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). Research indicates that its key active constituents, especially bacosides, offer neuroprotective effects through diverse pathways, such as acetylcholinesterase (AChE) inhibition, reduction of oxidative stress, anti-inflammatory actions, and modulation of neurotransmitter activity. Findings from both preclinical and clinical studies suggest improvements in memory, stress reduction, and overall cognitive enhancement, supporting its promise as a therapeutic candidate. Additionally, the plant's capability to facilitate the synthesis of metallic nanoparticles opens new avenues for innovative treatment approaches. However, challenges remain regarding the standardization of its extracts and validation of clinical efficacy. Future research should focus on clarifying its pharmacokinetic profile, creating standardized formulations, and conducting extensive clinical trials to establish its therapeutic value.